These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2189014)

  • 1. Tiazofurin: biological effects and clinical uses.
    Tricot G; Jayaram HN; Weber G; Hoffman R
    Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
    Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
    Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
    Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
    Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
    Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.
    Tricot GJ; Jayaram HN; Nichols CR; Pennington K; Lapis E; Weber G; Hoffman R
    Cancer Res; 1987 Sep; 47(18):4988-91. PubMed ID: 3476200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG; Boosalis M; Malek K; Waraska K
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
    Jayaram HN; Cooney DA; Grusch M; Krupitza G
    Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
    Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
    Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
    Sokoloski JA; Sartorelli AC
    Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog.
    Pani A; Marongiu ME; Pinna E; Scintu F; Perra G; Montis AD; Manfredini S; La Colla P
    Anticancer Res; 1998; 18(4A):2623-30. PubMed ID: 9703919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical issues in chemotherapy with tiazofurin.
    Weber G
    Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
    Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
    Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
    Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
    Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.